Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 925 shares at $18.94 ($18K) on 2025-01-22, disclosed to the SEC on 2025-01-23.
Seasonal sale ($18k) by SVP, CHIEF ACCOUNTING OFFICER — this insider has traded TVTX in January in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |